SK bioscience invests KRW 4.1B stake in a U.S. biotech

By Kim, Jin-Gu | translator Hong, Ji Yeon

24.10.10 05:44:48

가나다라 0

"Has core conjugate technology, including pneumoniae…we always expect an increase in immunogenicity·productivity"

"Has invested in three global companies this year…will continue to execute the strategy to grow"

SK bioscience announced on October 8th that the company has signed an agreement to acquire a stake in U.S. biotech Fina Biosolutions by investing USD 3 million (approximately KRW 4.1 billion). SK bioscience became the first and only strategic investor of Fina Biosolutions. According to the contract between both companies, the specific stake acquisition size remains undisclosed.

According to SK bioscience, Fina Biosolutions, established in 2006, has the core technology of conjugate vaccines for pneumoniae, meningococcus and typhoid.

Fina Biosolutions is known to manufacture 'CRM197 (cross-reacting material),' a protein carrier important for the conjugate vaccine development, and produce

Kim, Jin-Gu(kjg@dailypharm.com)

If you want to see the full article, please JOIN US (click)